PubMed Health⌕ Search

Biomedical subjects

B Mariańska

Publications and source records attributed to B Mariańska.

At least 19 recordsLinked to original sources
PubMed1991

[Morphological changes in peripheral blood and bone marrow in patients with myelodysplastic syndromes].

In 23 patients with myelodysplasia syndromes cytomorphological examinations of peripheral red blood cells and bone marrow cells were carried out. Apart from anisocytosis and poikilocytosis observed in all patients, the most frequent changes were macrocytosis and megalocytosis or erythrocytes and their precursors, presence of erythroblasts in peripheral blood and disturbances of megakaryopoiesis. None of these changes was characteristic in a given type of these syndromes.

Adult↗
PubMed1991

[Results of selected cytochemical studies of mature granulocytes in myelodysplastic syndromes and various other hematologic diseases].

The activity of alkaline phosphatase and peroxidase was measured in polymorphonuclears in 20 cases of myelodysplasia syndromes, 10 cases of chronic myeloid leukaemia. Reduced phosphatase activity was found in 5 cases and peroxidase activity in 3 cases of myelodysplasia syndromes. No evident correlation was noted between the activity of these enzymes and prognosis. Increased proportion of peroxidase-negative granulocytes was observed, moreover, in most cases of chronic myeloid leukaemia. The observations will be continued in larger material.

Alkaline Phosphatase↗
PubMed1991

[Preliminary results of the treatment of acute leukemia with mitoxantrone].

Mitoxantrone is a new anthracenodione derivative with a high antineoplastic activity in proliferative diseases of the haemopoietic system. In the Institute of Haematology in Warsaw and in the Department of Haematology, Silesian Medical Academy in Katowice this agent was used in combination with cytarabine in 49 cases of acute leukaemia (35 with acute myeloid leukaemia and 14 with acute lymphoblastic leukaemia). The preparations used were Mitoxantrone (POLFA Works in Jelenia Góra) and Novantrone (Lederle). These agents were given intravenously in doses of 10-20 mg/m2 for 3 days in combination with cytarabine in three doses: 100 mg/m2 on days 1 through 7, and 1 g/m2 or 3 g/m2 every 12 hours on days 1 through 4 of the treatment. Complete remission was obtained in 17 cases (35%), including 13 with acute myeloid leukaemia (37%) and 4 with acute lymphoblastic leukaemia (29). The most frequent side effects were: long-lasting pancytopenia (in 100% of cases), hair loss (39%) and gastrointestinal toxicity (33%). No significant differences were noted in the effectiveness and toxicity between these two preparations. In the light of the presented results it may be accepted that the combination of mitoxantrone with cytarabine is an important advance in the treatment of acute leukaemias.

Adolescent↗
PubMed1979

[Analysis of the results of treatment of multiple myeloma].

Therapeutic results were analysed in 62 cases of multiple myeloma treated by two-stage method: I. with cyclically non-specific agents (melphalan) in each case. When this treatment was a failure the second step was given: II. cyclically specific and non-specific agents by the M-2 schedule. Good therapeutic response was obtained in 70% of cases. The mean survival time in the whole group was 35 months, and in the subgroup with good prognosis it was 44 months. Most (74%) patients with IgG M-protein responded well to treatment with cyclically non-specific agents, while only 50% of those with IgA M-protein had a good response to them.

Adult↗
PubMedDate not supplied

[Preliminary observations on the results of treating malignant lymphoma with Lycurim].

The authors gave Lycurim to 30 patients with malignant lymphoma (LLC--12 cases, Hodgkin's disease - 15 cases, reticulosarcoma - 2 cases and lymphosarcoma - 1 case). The patients were divided into three groups. Group I received only Lycurim, group II - Lycurim and prednisone, group III - Lycurim and Solcoseryl. Significant improvement was observed in 22 patients, with complete remission in 5 cases and partial in 17 cases. Leucopenia and thrombocytopenia precluding treatment were never observed in cases treated simultaneously with prednisone or Solcoseryl. The authors believe that the proportion of remissions may be increased combining Lycurim with vincristine, procarbazine and glycocorticosteroids (LOP or LOPP).

Actihaemyl↗
PubMedDate not supplied

[Prognostic value of the peroxidase index in patients with acute nonlymphoblastic leukemia].

In 91 patients with acute non-lymphoblastic leukaemia the peroxidase index was determined in blast cells or promyelocytes in bone marrow. Complete remission was obtained exclusively in patients with the value of the index 0-9% or over 69%. The duration of the remission and the survival time were significantly longer in patients with a high peroxidase index. This index may be useful for prediction of the course of acute non-lymphoblastic leukaemia in adults and its high value is associated with better prognosis.

Bone Marrow↗
PubMedDate not supplied

[Analysis of 300 cases of secondary pancytopenia].

Clinical analysis of 300 cases of secondary pancytopenia treated in a period of 10 years is reported. The disease was more frequent in women than in men. The most frequent single cause were drugs, among them chloramphenicol. Most patients had pancytopenia and hypoplastic bone marrow. The mortality was 37%. Death occurred most frequently in the first 6 months of the disease due to infection or thrombocytopenic heamorrhagic diathesis. The results of treatment with corticosteroids and androgenic steroids were unsatisfactory.

Adolescent↗